The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab
Abstract
BACKGROUND: Gantenerumab is a fully human anti-Aβ monoclonal antibody in clinical development for the treatment of Alzheimer disease (AD). OBJECTIVES: To investigate whether treatment with gantenerumab leads to a measurable reduction in the level of Aβ amyloid in the brain and to elucidate the mechanism of amyloid reduction. DESIGN: A multicenter, randomized, double-blind, placebo-controlled, ascending-dose positron emission tomographic study. Additionally, ex vivo studies of human brain slices from an independent sample of patients who had AD were performed. SETTING: Three university medical centers. PATIENTS: Patients with mild-to-moderate AD. INTERVENTION: Two consecutive cohorts of patients received 2 to 7 infusions of intravenous gantenerumab (60 or 200 mg) or placebo every 4 weeks. Brain slices from patients who had AD were coincubated with gantenerumab at increasing concentrations and with human microglial cells. MAIN OUTCOME MEASURES: Percent change in the ratio of regional carbon 11-labeled Pittsburgh Compound B retention in vivo and semiquantitative assessment of gantenerumab-induced phagocytosis ex vivo. RESULTS: Sixteen patients with end-of-treatment positron emission tomographic scans were included in the analysis. The mean (95% CI) percent change from baseline difference relative to placebo (n = 4) in cortical brain amyloid level was -15.6% (95% CI, -42.7 to 11.6) for the 60-mg group (n = 6) and -35.7% (95% CI, -63.5 to -7.9) for the 200-mg group (n = 6). Two patients in the 200-mg group showed transient and focal areas of inflammation or vasogenic edema on magnetic resonance imaging scans at sites with the highest level of amyloid reduction. Gantenerumab induced phagocytosis of human amyloid in a dose-dependent manner ex vivo. CONCLUSION: Gantenerumab treatment resulted in a dose-dependent reduction in brain amyloid level, possibly through an effector cell-mediated mechanism of action.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This antibody can disassemble and degrade amyloid plaques by recruiting microglia and activating phagocytosis [71,72].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [72]
In the citing paper
“Several anti-Aβ monoclonal antibodies (mAbs) have been tested in clinical trials in AD patients and were found to significantly reduce load of fibrillar Aβ as demonstrated using PET Aβ imaging [5–8].”
From APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice (2017) · cites this paper as [6]
Citations
Cites
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490
Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report
Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397
Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization
Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000073623.84147.a8 · Cited by 1,356
Pathological verification of ischemic score in differentiation of dementias
Rosen, W. G., Terry, R. D., Fuld, P. A., Katzman, R., & Peck, A. (1980) · Annals of Neurology · doi:10.1002/ana.410070516 · Cited by 1,273
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., Lopresti, B. J., Ziolko, S., Bi, W., Paljug, W. R., et al. (2008) · Brain · doi:10.1093/brain/awn016 · Cited by 933
Sperling, R. A., Jack, C. R., Black, S. E., Frosch, M. P., Greenberg, S. M., Hyman, B. T., Scheltens, P., Carrillo, M. C., Thies, W., Bednar, M. M., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2351 · Cited by 857
Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease
Villemagne, V. L., Pike, K. E., Chételat, G., Ellis, K. A., Mulligan, R. S., Bourgeat, P., Ackermann, U., Jones, G., Szoeke, C., Salvado, O., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22248 · Cited by 833
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c67808 · Cited by 753
Rinne, J. O., Brooks, D. J., Rossor, M. N., Fox, N. C., Bullock, R., Klunk, W. E., Mathis, C. A., Blennow, K., Barakos, J., Okello, A. A., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70043-0 · Cited by 701
Cited by
Sorted by citations
Items 401–430 of 430
Genomics of Alzheimer’s disease
Rosenberg, R. N., Lambracht‐Washington, D., Yu, G., & Xia, W. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19176-3.00035-2
An, D., Li, X., & Xu, Y. Y. (2025) · Medical Hypotheses · doi:10.1016/j.mehy.2025.111576
Trends in Research on Gantenerumab for Alzheimer’s Disease: A Bibliometric and Thematic Analysis
Abdelwahab, S. İ., Taha, M. M. E., Alfaifi, H. A., Alzahrani, A. H., Aljahdali, I. A., Oraibi, O., Ali, S., Oraibi, B., Farasani, A. M., Jerah, A. A., et al. (2025) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/0118715273349645250324040257
Amyloid- and Tau-Targeted Therapies in Alzheimer’s Disease
Rajic, A. J., Galasko, D. R., & Tuszynski, M. H. (2025) · Springer eBooks · doi:10.1007/978-3-031-89307-0_17
Taylor, X., Clark, I., Fitzgerald, G. J., Oluoch, H., Hole, J. T., Demattos, R. B., Wang, Y., & Pan, F. (2024) · Figshare · doi:10.6084/m9.figshare.26613967
Taylor, X., Clark, I., Fitzgerald, G. J., Oluoch, H., Hole, J. T., Demattos, R. B., Wang, Y., & Pan, F. (2024) · Figshare · doi:10.6084/m9.figshare.26613961
Taylor, X., Clark, I., Fitzgerald, G. J., Oluoch, H., Hole, J. T., Demattos, R. B., Wang, Y., & Pan, F. (2024) · Figshare · doi:10.6084/m9.figshare.26613973
Taylor, X., Clark, I., Fitzgerald, G. J., Oluoch, H., Hole, J. T., Demattos, R. B., Wang, Y., & Pan, F. (2024) · Figshare · doi:10.6084/m9.figshare.26613964
Taylor, X., Clark, I., Fitzgerald, G. J., Oluoch, H., Hole, J. T., Demattos, R. B., Wang, Y., & Pan, F. (2024) · Figshare · doi:10.6084/m9.figshare.26613985
Taylor, X., Clark, I., Fitzgerald, G. J., Oluoch, H., Hole, J. T., Demattos, R. B., Wang, Y., & Pan, F. (2024) · Figshare · doi:10.6084/m9.figshare.26613979
Taylor, X., Clark, I., Fitzgerald, G. J., Oluoch, H., Hole, J. T., Demattos, R. B., Wang, Y., & Pan, F. (2024) · Figshare · doi:10.6084/m9.figshare.26613958
Taylor, X., Clark, I., Fitzgerald, G. J., Oluoch, H., Hole, J. T., Demattos, R. B., Wang, Y., & Pan, F. (2024) · Figshare · doi:10.6084/m9.figshare.26613982
Taylor, X., Clark, I., Fitzgerald, G. J., Oluoch, H., Hole, J. T., Demattos, R. B., Wang, Y., & Pan, F. (2024) · Figshare · doi:10.6084/m9.figshare.26613988
Taylor, X., Clark, I., Fitzgerald, G. J., Oluoch, H., Hole, J. T., Demattos, R. B., Wang, Y., & Pan, F. (2024) · Figshare · doi:10.6084/m9.figshare.26613970
Taylor, X., Clark, I., Fitzgerald, G. J., Oluoch, H., Hole, J. T., Demattos, R. B., Wang, Y., & Pan, F. (2024) · Figshare · doi:10.6084/m9.figshare.26613976
Schwab, D., Hofmann, C., Justies, N., Dickerson, D., Keshavarz, A., van Iersel, T. M., Martens, K., & Bittner, B. (2026) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.70038
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9.05
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9.references
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9.07
Third Section: Design of a dimeric-nanobody specific for Aβ42 oligomers: the Dimeric-DesAb-O
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9.06
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9.03
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9.04
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9.02
Conclusion and Future Perspectives
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9.08
Natural Products as Effective Treatment Approach for Alzheimer's Disease: In silico Justification
Khamkat, P., Chatterjee, B. K., Barık, V., Sahu, S., & Mukherjee, S. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898815646126010015
Mukherjee, S., Barthélemy, N. R., Atri, T. E., Wang, Q., Yen, D. P., He, Y., Coyle, R. A., Ovod, V., Franklin, E. E., Xiong, C., et al. (2026) · medRxiv · doi:10.64898/2026.09.22.26363432
Longitudinal clinical outcomes after amyloid clearance in aducanumab phase 3 studies
Pang, M., Brothers, H. M., Ogorman, J., Murphy, J., Zabar, Y., Lasky, T., Shen, C., Rubino, I., & Knopman, D. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71758
Metadata
- Authors
- Ostrowitzki, S.
- Affiliations
- F. Hoffmann-La Roche AG (CH)
- Corresponding author
- Ostrowitzki, Susanne
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2012-02-01
- Volume
- 69
- Issue
- 2
- Pages
- 198
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2118753807
- Cited by
- 431
- References
- 19
- Citations by year
- 2026: 18 · 2025: 17 · 2024: 34 · 2023: 22 · 2022: 22 · 2021: 24 · 2020: 18 · 2019: 23 · 2018: 30 · 2017: 34 · 2016: 39 · 2015: 31 · 2014: 44 · 2013: 45 · 2012: 24
- FWCI
- 25.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Archives of Neurology (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- gantenerumab, Alzheimer's disease, amyloid-beta, anti-amyloid monoclonal antibodies, phagocytosis, microglia, Pittsburgh compound B, dose-dependent effects, vasogenic edema
- MeSH terms
- Aged, Alzheimer Disease, Aniline Compounds, Antibodies, Monoclonal, Brain Chemistry, Cell Count, Double-Blind Method, Female, Follow-Up Studies, Humans, Immunoglobulin G, Injections, Intravenous, Male, Middle Aged, Phagocytosis, Thiazoles, Cohort Studies, Amyloid beta-Peptides, Microglia, Sample Size, Radiopharmaceuticals, Alzheimer Vaccines, Positron-Emission Tomography, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
